Absci Corporation will be presenting preclinical data for ABS-101, an anti-TL1A antibody program, this week at the 42nd Annual J.P. Morgan Healthcare Conference. Absci’s Integrated Drug Creation platform designed over 50 antibody leads with subnanomolar affinity using its de novo generative AI foundation model, enabling a diversity of potential candidates. Absci has selected three potential candidates for the ABS-101 program utilizing its AI lead optimization capabilities. In preclinical studies, ABS-101 potential candidates exhibited properties consistent with a potentially superior product profile by demonstrating equal or superior potency data from multiple biophysical and cellular assays, in addition to improved developability properties, as compared to estimated performance of a putative clinical competitor molecule in later stages of development. These attributes support the program’s potential to create an efficacious candidate conducive to subcutaneous dosing. Furthermore, in vitro and preliminary in vivo PK studies confirm the potential for extended half-life, supporting the objective for significantly improved dosing intervals. These preclinical results demonstrate the ability of Absci’s generative AI platform to rapidly and efficiently create differentiated antibody drug candidates. Supporting data for these assessments can be found in the associated company presentation for the upcoming J.P. Morgan Healthcare Conference, published on Absci’s investor relations website. Absci expects to initiate Investigational New Drug application enabling studies for ABS-101 in February 2024, and submit an IND in the first quarter of 2025. Subject to clearance of the IND, Absci expects to initiate Phase 1 studies for this program shortly thereafter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABSI:
- Absci to Participate in the 26th Annual Needham Growth Conference
- Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
- Absci, PrecisionLife enter R&D partnership for AI-enabled drug pipeline
- Absci management to meet virtually with William Blair